



Please send the enclosure to:

MHP Münchner Hämatologie Praxis  
in Zusammenarbeit mit dem  
MLL Münchner Leukämie Labor  
P.O. Box 20 14 53  
80014 Munich

Telephone: +49 (0)89 990170  
Email: info@mll.com

.....

## Patient Consent – MLL Research Projects

I have been informed of the research activities of MLL through MLL's information sheet on data processing and the use of biomaterial as well as the additional information available at [www.mll.com](http://www.mll.com). I would like to support the research activities of MLL and consent to the use of my excess biomaterial for research purposes. Based on the information of MLL, I understand that I am donating my biomaterial for research purposes and will not share in any financial proceeds from the research using my biomaterial or health data.

Additional (*please tick the box, if desired*):

If MLL gains any new medical knowledge about me, I agree that MLL will inform me of this knowledge without prior request.

I may revoke my consent and agreement to be contacted in the case of new knowledge at any time and also separately with effect for the future. Notice of my revocation may be sent by mail to MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich, electronically using the email address [info@mll.com](mailto:info@mll.com) or by fax to 089-99017111.

\_\_\_\_\_  
Date, Signature

\_\_\_\_\_  
First name, Last name

\_\_\_\_\_  
Date of Birth

\_\_\_\_\_  
Street

\_\_\_\_\_  
Postal Code, City

## Münchener Leukämielabor (MLL)

### Information on Data Processing and the Use of Biomaterial

**Münchener Leukämielabor (MLL<sup>1</sup>)** is a medically and scientifically interdisciplinary practice with a specialized laboratory. MLL focuses on optimized, safe and rapid leukemia diagnostics for a large number of leukemia cases using a comprehensive spectrum of diagnostic methods. Hand in hand with providing medical care to patients from Germany and abroad, the physicians and scientists of MLL are continuously engaged in research with great success in order to improve leukemia diagnostics and the treatment of leukemia. The medical scientific research projects of MLL and its cooperation partners serve to improve the understanding of the origin, development and diagnosis of disease. On this basis, MLL develops new and improved approaches for prevention, care and treatment.

**Cooperation and Research.** The members of MLL cooperate closely in providing medical care to patients and in medical scientific research. In addition, MLL cooperates with selected institutions in the analysis and research of tissue samples and body fluids (biomaterials) and medical databases. This takes place in the context of scientific studies or projects (research projects) in order to be able to detect, prevent and combat disease better. These research projects are indispensable in order to be able to treat leukemia and other serious diseases even better in the future. Insights gained from the analysis of patient data and biomaterials are extremely important for the further development of diagnostic capabilities and the treatment of disease, including drug therapy.

For research projects, MLL uses biomaterial and health data from patients in coordination with the responsible bodies, in particular the responsible independent ethics committee(s). In the context of collaborations, MLL receives expense allowances or fees from public bodies or private cooperation partners, depending on the nature and objective of the research project, for its contributions to the research project.

**Processing of Health Data and Biomaterial.** When providing medical care to patients and conducting its research activities, MLL processes health data of patients and biomaterial. The biomaterial used for research is obtained from blood samples, biopsies or surgical procedures performed on patients; so-called “excess” biomaterial that is not needed for medical care is used for research.

MLL analyzes health data and biomaterials depending on the request for testing and medical necessity. Health data includes, for example, information arising from the examination and treatment of patients, such as the results of a blood pressure measurement or laboratory tests, but above all also genetic data of patients. In particular, MLL analyzes combinations (chromosomes) and components (nucleic acids) of genetic material specifically for genetic changes in blood or bone marrow cells.

MLL stores all health data in a protected database. Likewise, MLL securely stores biomaterials (tissue samples and body fluids) of its patients. The quality-controlled and state-of-the-art long-term storage of biomaterials takes place in biobanks and archives of MLL.

---

<sup>1</sup> “MLL” includes: MLL Münchener Leukämielabor GmbH, MHP Münchener Hämatologie Praxis PartG (MHP), MLLI GmbH and MLL Dx GmbH, all in Munich, Max-Lebsche-Platz 31; only MHP practices “medicine” within the meaning of medical patient care.

**Identity Protection of Patients.** Not only during the course of medical treatment, but also in the context of research projects, MLL processes and protects personal data and biomaterial in such a way that reference to a patient can only be established by using special information keys, which MLL keeps safe and protects against access by third parties, for example, by assigning a specific allocation code and storing personally identifiable data separately. Because only MLL has the corresponding allocation key, MLL is still able to provide medical treatment without MLL's cooperation partners or others being able to identify patients. This also applies in particular for research partners in the medical or pharmaceutical industry who would like to engage MLL to conduct medical research studies or use MLL's patient research data to develop diagnostic methods or drugs. Scientific publications of MLL and its cooperation partners are made exclusively in a form that does not allow for any conclusions to be drawn about individual persons.

However, it is possible that in the course of further analyzing health data and biomaterial, chromosomal characteristics may be discovered that may be relevant for both the patient's medical care and that of his or her descendants. Patients can decide whether they would like to be actively contacted in the case of such new findings.

**Use of Biomaterial and Health Data for Research with the Consent of Patients.** Excess biomaterial and health data, especially genetic data, are - as described - of great importance for medical scientific research projects. Our patients decide whether they want to give excess biomaterial to MLL so that it can be used for research. With the patient's consent, the biomaterial becomes the property of MLL and is retained by MLL for a time period during which the material may be useful for research to a reasonable extent. The biomaterial is used for MLL's own research and is made available to third parties for research purposes. Consenting patients "donate" excess biomaterial and data for scientific research. Patients do not receive any financial consideration for their consent even if the research results are used commercially (e.g., by selling newly developed drugs or diagnostic procedures). Patients who do not give their consent naturally do not suffer any disadvantages in terms of their medical care provided by MLL.

MLL processes patients' health data for research purposes, applying the privileges granted by law, in particular by data protection law, in the interests of further developing the diagnosis and treatment of disease as described above.

**Further Information.** Our patients can find more detailed information about MLL on the website <https://www.mll.com/datenschutz.html>. The above explanations together with further information on the processing of patient data can be found on the website through which MLL provides information on the processing of patient data in accordance with the applicable data protection regulations. The data protection information is also available in the reception area of MLL.